Xspray Pharma Announces SEK 130 Million Rights Issue and Loan Refinancing

Xspray Pharma AB ( (SE:XSPRAY) ) just unveiled an update.

Xspray Pharma AB has announced a rights issue of approximately SEK 130 million, with an additional over-allotment issue, to support the launch of its product Dasynoc in the U.S. market and advance the FDA process for XS003-nilotinib. The company is also refinancing its existing loan, extending its maturity by 18 months and increasing it by SEK 25 million, to secure funding through to the expected cash flow break-even point in the second half of 2026. This strategic financial move demonstrates strong shareholder and investor confidence in Xspray’s commercialization plans and is crucial for its continued development and market positioning.

More about Xspray Pharma AB

Xspray Pharma AB is a pharmaceutical company specializing in the development of improved versions of marketed protein kinase inhibitors (PKIs) for cancer treatment. Utilizing its patented HyNap technology, Xspray focuses on creating amorphous formulations of selected drugs, targeting the oncology segment where drug prices are typically high.

Average Trading Volume: 34,510

Technical Sentiment Signal: Buy

Current Market Cap: SEK1.91B

See more insights into XSPRAY stock on TipRanks’ Stock Analysis page.